Business Wire

Crown Bioscience Increases APAC Capacity with New Facility in Zhongshan, China

Share

Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/

CrownBio's New Zhongshan, China Facility (Photo: Business Wire)

CrownBio's New Zhongshan, China Facility (Photo: Business Wire)

In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.

CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.

The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.

“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.

A site opening event and ribbon cutting ceremony will take place on October 30th 2020.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:

https://www.crownbio.com

https://www.jsrlifesciences.com

Contact information

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

93rd Vifor Pharma Group Annual General Meeting6.5.2021 19:00:00 EEST | Press release

Regulatory News: At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 pandemic and in accordance with Ordinance 3 on measures to combat the coronavirus issued by the Swiss Federal Council, on the basis of Art. 8 of the new COVID-19 Act, shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 61.6% of the share capital was represented. Shareholder approvals Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd., as well as the consolidated Financial Statements of Vifor Pharma Group for 2020 by a large majority. The maximum possible 2022 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2020 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of th

Aerobiotix Raises $25M Growth Equity Financing Led by Global Healthcare Investment Firm Vivo Capital6.5.2021 18:22:00 EEST | Press release

Founded in 2013, Aerobiotix, a rapidly growing global medical company has raised a $25 million of growth equity financing. The round was led by Vivo Capital with participation by Asahi Kasei Ventures. The new funding will be used to accelerate sales, marketing, and new product development. The Company’s infection control products have been used to support thousands of procedures across multiple surgical specialty disciplines and in over 175 hospitals and multiple long-term care facilities. Aerobiotix has developed a novel suite of FDA 510(k) cleared hospital-based air decontamination products and its devices are supported by multiple peer-reviewed research studies. Aerobiotix devices, such as the operating-room based ILLUVIA® system, are used by leading healthcare centers to reduce bacterial and viral contamination, including SARS-CoV-2 and other emerging pathogens. Aerobiotix products provide mechanical and ultraviolet filtration to remove airborne threats with high efficiency to prot

Elevēo Recognized in 2021 Gartner Magic Quadrant for Workforce Engagement Management Report6.5.2021 16:52:00 EEST | Press release

Elevēo announced today that global research and advisory firm, Gartner, has named Elevēo in its 2021 Magic Quadrant for Workforce Engagement Management.[1] “Eleveo has been recognized in this Gartner Magic Quadrant for Work Engagement Management for the 8th time*,” says Barry Williams, VP of Product and Marketing at Elevēo. He believes Elevēo is unique among the WEM solution providers included in this year’s magic quadrant. “We’re privately held and have grown our customer base and product suite organically - entirely without benefit of merger or acquisition. We believe that this recognition is a testament to the effort and dedication of our product and development teams, who’re continuously pushing us to be one of the top vendors in the WEM space.” Among key modules Elevēo added to its scalable WEM solution in 2020 are an Agent Desktop Toolbar, which automatically pauses and resumes recording to protect PCI or other sensitive data, and Multi-Skill/Multi-Channel forecasting and schedul

Vantage Data Centers Provides Renewable Energy Options to Customers at All Campuses Globally6.5.2021 15:30:00 EEST | Press release

Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced that it now provides access to renewable energy options at each of its North American and European campuses to enable customers to reduce their carbon emissions. Additionally, the company has hired two experts to lead its environmental sustainability commitments across the globe. Four of the company’s campuses are currently powered by more than 99% renewable energy (hydro, tidal and wind) for critical IT load through Vantage’s utility partners, while the other campuses provide access to green power purchases and renewable energy credits through local utility partners. Vantage actively works with energy providers, customers and industry groups to advocate and invest in additional renewable energy options globally. As part of an expanded focus on environmental goals, the company named Amanda Sutton as senior director of sustainability to lead Vantage’s global sustainability program to less

Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions6.5.2021 14:00:00 EEST | Press release

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, has entered into an agreement with Exeltis (“Exeltis”) (a division of the global pharmaceutical group Insud Pharma) to develop, manufacture and commercialize a novel preclinical candidate from Aptorum in the following territories: the European Union and Latin America (with an option to expand the collaboration to the United States). This novel candidate is intended to target woman’s health and gynecological conditions, such as endometriosis or related conditions. Under the Agreement, Aptorum Group will retain the development rights in other jurisdictions in the world, as well as the right to develop the novel candidate into a drug product. Commercialisation of the product is subject to relevant regulatory approvals in their respective jurisdictions. Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented:

FedEx Delivering Critical COVID-19 Aid to India6.5.2021 14:00:00 EEST | Press release

As India and its healthcare systems face a surge in COVID-19 infections across the country, FedEx Express, a subsidiary of FedEx Corp. (NYSE: FDX) and the world’s largest express transportation company, is working with organizations around the world to deliver critical medical supplies and equipment during this crisis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005392/en/ Critical medical supplies and personal protective equipment departing Santa Barbara, Calf., USA, bound for healthcare facilities in Kolkata, India via FedEx. (Photo: Business Wire) FedEx is currently supporting the transportation of more than 25,000 oxygen concentrators and converters through an initiative with the U.S.-India Strategic Partnership Forum and other multinational companies. An initial shipment of 1,000 critical oxygen concentrators was delivered by FedEx to New Delhi on April 30 as part of this collective. On May 8, FedEx is donating

SoftServe Charity Fund Opens ‘Positive Room’ at Dnipro Regional Children's Hospital6.5.2021 14:00:00 EEST | Press release

SoftServe’s corporate charity fund, “Open Eyes” has opened a “Positive Room” for patients of the Dnipro Regional Children’s Clinical Hospital. The Positive Room in Dnipro, the sixth such space in Ukraine, was opened at the Department of Reconstructive Surgery thanks to charitable donations by SoftServe, its employees, and other contributors. The Department helps as many as 30 children at a time recover from the most serious, life-threatening illnesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005004/en/ “Positive Room” for patients of the Dnipro Regional Children’s Clinical Hospital. (Photo: Business Wire) “We treat children with the most serious diseases: congenital malformations, chemical burns of the esophagus, disorders of the gastrointestinal tract, and tumors requiring surgery,” said Oleksandr Gladkyi, head of the Department of Reconstructive Surgery of Dnipro Regional Children's Clinical Hospital. “The roo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom